Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Susana Maria Campos, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Susana Campos and Ursula Matulonis.
Susana Campos
Connection Strength
3.470
Ursula Matulonis
  1. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794.
    View in: PubMed
    Score: 0.208
  2. Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecol Oncol. 2019 07; 154(1):95-101.
    View in: PubMed
    Score: 0.204
  3. Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. Gynecol Oncol. 2019 06; 153(3):471-478.
    View in: PubMed
    Score: 0.202
  4. Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol. 2015 Aug; 76(2):417-23.
    View in: PubMed
    Score: 0.156
  5. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013 Feb; 128(2):215-20.
    View in: PubMed
    Score: 0.128
  6. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):41-6.
    View in: PubMed
    Score: 0.125
  7. Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function. J Psychosoc Oncol. 2012; 30(4):387-401.
    View in: PubMed
    Score: 0.122
  8. The use of bevacizumab and concurrent radiation for recurrent gynecologic cancers. J Clin Oncol. 2011 May 20; 29(15_suppl):5101.
    View in: PubMed
    Score: 0.117
  9. Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol. 2010 Aug; 15(4):390-8.
    View in: PubMed
    Score: 0.109
  10. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9.
    View in: PubMed
    Score: 0.106
  11. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6.
    View in: PubMed
    Score: 0.105
  12. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol. 2009 Aug; 114(2):353-9.
    View in: PubMed
    Score: 0.102
  13. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec 10; 26(35):5761-6.
    View in: PubMed
    Score: 0.098
  14. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008 Sep; 122(3):574-80.
    View in: PubMed
    Score: 0.095
  15. Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5523.
    View in: PubMed
    Score: 0.095
  16. Anaphylactic and anaphylactoid reactions to chemotherapy: outcomes and safety of rapid intravenous and intraperitoneal desensitizations in 413 cases. J Clin Oncol. 2008 May 20; 26(15_suppl):5526.
    View in: PubMed
    Score: 0.095
  17. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. J Clin Oncol. 2008 May 20; 26(15_suppl):5528.
    View in: PubMed
    Score: 0.095
  18. Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen. Gynecol Oncol. 2006 Nov; 103(2):575-80.
    View in: PubMed
    Score: 0.083
  19. Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5085.
    View in: PubMed
    Score: 0.083
  20. Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol. 2006 Oct; 103(1):160-4.
    View in: PubMed
    Score: 0.082
  21. A phase II trial of modified triple doublets for the treatment of advanced Müllerian malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):5010.
    View in: PubMed
    Score: 0.077
  22. Long-acting octreotide for the treatment of symptoms of bowel obstruction in advanced ovarian cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):5159.
    View in: PubMed
    Score: 0.077
  23. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol Oncol. 2005 Jan; 96(1):198-203.
    View in: PubMed
    Score: 0.075
  24. A phase II study of fixed dose-rate gemcitabine in patients with relapsed Müllerian tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5151.
    View in: PubMed
    Score: 0.073
  25. A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. Gynecol Oncol. 2003 Nov; 91(2):293-8.
    View in: PubMed
    Score: 0.069
  26. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours. Br J Cancer. 2022 Apr; 126(7):1027-1036.
    View in: PubMed
    Score: 0.061
  27. A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. Cancer. 2001 Sep 01; 92(5):1156-67.
    View in: PubMed
    Score: 0.060
  28. Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2021 09; 162(3):661-666.
    View in: PubMed
    Score: 0.059
  29. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol. 2001 May; 81(2):206-12.
    View in: PubMed
    Score: 0.058
  30. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 05 10; 39(14):1531-1539.
    View in: PubMed
    Score: 0.058
  31. Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecol Oncol. 2021 05; 161(2):581-586.
    View in: PubMed
    Score: 0.058
  32. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020 10; 159(1):72-78.
    View in: PubMed
    Score: 0.055
  33. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2016 May-Jun; 4(3):497-504.
    View in: PubMed
    Score: 0.041
  34. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol. 2016 Apr; 137(4):1154-1164.e12.
    View in: PubMed
    Score: 0.040
  35. Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol. 2012 May; 125(2):510-1.
    View in: PubMed
    Score: 0.031
  36. Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5020.
    View in: PubMed
    Score: 0.021
  37. A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors. Int J Gynecol Cancer. 2005 Nov-Dec; 15(6):1035-41.
    View in: PubMed
    Score: 0.020
  38. A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. Br J Cancer. 2005 Jul 11; 93(1):54-9.
    View in: PubMed
    Score: 0.020
  39. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res. 2005 Jun 15; 11(12):4430-6.
    View in: PubMed
    Score: 0.019
  40. Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: A protocol effective in patients with gynecologic malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):5090.
    View in: PubMed
    Score: 0.019
  41. Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. Gynecol Oncol. 2004 Jun; 93(3):702-7.
    View in: PubMed
    Score: 0.018
  42. Phase II trial of anastrozole in women with asymptomatic müllerian cancer. Gynecol Oncol. 2003 Dec; 91(3):596-602.
    View in: PubMed
    Score: 0.017
  43. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol. 2002 Sep; 86(3):302-10.
    View in: PubMed
    Score: 0.016
  44. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
    View in: PubMed
    Score: 0.015
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.